樂觀
$89.49
情境價格
$94.230
+1.234 (+1.31%)收盤時
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
Medtronic PLC appears to be a good buy at the current price of $88.48, especially given its strong fundamentals and positive catalysts. The company raised its dividend for the 49th consecutive year, indicating a commitment to shareholder returns, and analysts project a revenue growth of 7.25%-7.75% for fiscal 2027. However, the stock has faced challenges, reflected in a 7.88% year-to-date decline. The forward P/E ratio is attractive at 14.93, suggesting potential for upside.
BTIG
$99
2026-10-12
BTIG
2026-10-12
目標價
$99
Barclays
$95
2026-10-06
Barclays
2026-10-06
目標價
$95
Deutsche Bank
$92
2026-09-03
Deutsche Bank
2026-09-03
目標價
$92
UBS
$110
2026-09-03
UBS
2026-09-03
目標價
$110
Mizuho
$115
2026-09-02
Mizuho
2026-09-02
目標價
$115
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Boeing Board Restructuring Boosts Confidence

Investment Insights: Focus on McKesson and Medtronic

Medtronic Completes MiniMed Share Exchange

Intensifying Competition in Pharma Sector: Investor Focus Required

Medtronic's Share Exchange Offer Oversubscribed
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).
Medtronic PLC appears to be a good buy at the current price of $88.48, especially given its strong fundamentals and positive catalysts. The company raised its dividend for the 49th consecutive year, indicating a commitment to shareholder returns, and analysts project a revenue growth of 7.25%-7.75% for fiscal 2027. However, the stock has faced challenges, reflected in a 7.88% year-to-date decline. The forward P/E ratio is attractive at 14.93, suggesting potential for upside.
23 analysts cover MDT: 11 rate it Buy, 12 Hold and 0 Sell. The average price target is 111.76.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。